Company intelligence / Profile preview

Spiderwort

Ottawa, Ontario, Canadaspiderwortbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Spiderwort has developed a proprietary cellulose-based biomaterial platform with two lead programs—CelluBridge® for spinal cord injury repair and CelluJuve® as a dermal filler for facial aesthetics. Both are in preclinical or early-stage development; no published clinical results yet.

Therapeutic areas: DermatologyNeurology
Modalities: DeviceBiomaterial (cellulose-based scaffold)Non-pharmacological therapy (tissue engineering scaffolds)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

CelluBridge

Pre-clinical

Indications: Spinal cord injury

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Spiderwort.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spiderwort.

Explore the full profile